A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer - PACIFIC-9

Exclusion Criteria

• - History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥5 years before the first dose of study intervention and of low potential risk for recurrence, adequately resected non-melanoma skin cancer and curatively treated in situ disease, or adequately treated carcinoma in situ or Ta tumours without evidence of disease.
• - Mixed small cell and non-small cell lung cancer histology.
• - Participants who receive sequential (not inclusive of induction) chemoradiation therapy for locally advanced (Stage III) unresectable NSCLC.
• - Participants with locally advanced (Stage III) unresectable NSCLC who have progressed during platinum-based cCRT.
• - Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy (excluding alopecia).
• - Participants with ≥grade 2 pneumonitis from prior chemoradiation therapy.
• - History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or idiopathic pneumonitis – regardless of time of onset prior to randomisation. Evidence of active non-CRT induced pneumonitis (≥ Grade 2), active pneumonia, active ILD, active or recently treated pleural effusion, or current pulmonary fibrosis - diagnosed in the past 6 months prior to randomization.
• - Active or prior documented autoimmune or inflammatory disorders (with exceptions)
• - Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.